Novo Nordisk has announced that it will sell its blockbuster Wegovy and Ozempic drugs through the US telehealth company Hims & Hers Health later this month.
The pharma giant has also dropped its lawsuit against Hims & Hers "without prejudice," according to a statement made by Hims.
Under the agreement, Hims will no longer offer compounded GLP-1s on its platform or in its marketing materials. Existing patients will be given the opportunity to transition to FDA-approved medicines when their providers determine it is clinically appropriate.
However, the telehealth company can offer compounded GLP-1s if a provider determines that a compounded product is clinically necessary.
Hims will offer both Ozempic 0.5 mg, 1 mg and 2 mg injections and Wegovy pills and injections on the platform later this month, including 1.7 mg and 2.4 mg injections and 1.5 mg, 4 mg, 9 mg and 25 mg tablets.
Novo Nordisk CEO, Mike Doustdar, called the agreement a "meaningful win" for US patients.
"By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy," he said.
"Wegovy is not simply an obesity therapy. It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease."
We all want better health. Our goal is simple: ensure that every patient who can benefit from our medicines has the opportunity to access them, wherever they choose to receive care.
"We see tremendous growth opportunities in the US with the expanding assortment of branded GLP-1 medications," added Andrew Dudum, co-founder and CEO of Hims & Hers.
"I'm excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people."
This collaboration reflects what's possible globally when drugmakers, biotech companies and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.
Last month, the FDA had said that it would take decisive steps against companies mass-marketing illegal copycat drugs, including Hims, which had prompted the company to U-turn on selling a copy of Novo's pill.
In a post on X, FDA commissioner Marty Makary wrote that he was "Glad to see HIMS will stop advertising unapproved compounded drugs and instead sell FDA-approved products through its new partnership with Novo Nordisk."
Glad to see HIMS will stop advertising unapproved compounded drugs and instead sell FDA-approved products through its new partnership with Novo Nordisk. Importantly, they will keep them affordable (no increase in price) and limit compounded GLP-1s for rare (FDA compliant) cases.…
— Dr. Marty Makary (@DrMakaryFDA) March 9, 2026